David A. Siegel Palisade Bio, Inc. Transaction History

Two Sigma Advisers, LP

  • $41.3 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022
SELL
$0.81 - $1.51 $8,505 - $15,855
-10,500 Closed
0 $0
Q4 2021

Feb 14, 2022
BUY
$1.3 - $2.96 $13,650 - $31,080
10,500 New
10,500 $14,000

About PALISADE BIO, INC.

PALI Quotes by TradingView
  • Ticker PALI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,240,200
  • Market Cap $122M
  • Description
  • Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzym...
More about PALI
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email